12 results
6-K
EX-99.1
GLPG
Galapagos NV
27 Oct 20
Current report (foreign)
12:13pm
cytokines. Today, Galapagos also presents new preclinical and healthy volunteer data, and details its broad program to discover and develop multiple
6-K
EX-99.1
GLPG
Galapagos NV
24 Feb 22
Galapagos 2021 results set stage for future growth
5:19pm
compounds with improved pharmacology and selectivity profiles, and plan to select a preclinical candidate to move into a healthy volunteer study
6-K
EX-99.2
GLPG
Galapagos NV
5 Aug 21
Galapagos reports H1 financial results with refocused pipeline and operational progress
4:02pm
volunteer Phase 1 study in 2022.
We are also proud of the progress achieved to date with our European commercial launch of filgotinib, under the brand name
6-K
EX-99.2
GLPG
Galapagos NV
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
evidence of the potential dual mode of action of SIK2/3. We plan to bring an SIK2/3 molecule with optimized pharmacology into a healthy volunteer
6-K
EX-99.2
ddluos1qrqg5ai94pt12
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
424B5
zvqyuv3o
18 Apr 17
Prospectus supplement for primary offering
12:00am
424B5
quxiqv iih8t7zl4bn
17 Apr 17
Prospectus supplement for primary offering
12:00am
- Prev
- 1
- Next